Müllerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications
Jose Teixeira,
Shyamala Maheswaran and
Patricia K. Donahoe
Pediatric Surgical Research Laboratories, Department of Surgery,
Massachusetts General Hospital and Harvard Medical School, Boston,
Massachusetts 02114
Correspondence: Address all correspondence and requests for reprints to: Jose Teixeira, Pediatric Surgery/WRN1024, 32 Fruit Street, Boston, Massachusetts 02114. E-mail: teixeira{at}helix.mgh.harvard.edu
Dr. Alfred Jost pioneered the field of reproductive endocrinology
withhis seminal observation that two hormones produced by the testes
arerequired for the male embryo to develop a normal internal
reproductivetract. T induces the Wolffian ducts to differentiate into
epididymides,vasa deferens, and seminal vesicles. Müllerian
inhibitingsubstance (MIS) causes regression of the Müllerian
ducts,which in its absence would normally develop into the Fallopian
tubes,uterus, and upper vagina as is observed in female embryos. This
reviewwill summarize our current understanding of molecular mechanisms
underlyingthe function of MIS both as a fetal gonadal hormone that
causesMüllerian duct regression and as an adult hormone, the
rolesfor which are currently being investigated, i.e.,
inhibitionof steroidogenesis, germ cell development, and cancer. We
willalso address the regulation of MIS expression as one of thefirst
genes expressed after the commitment of the bipotentialgonads to
differentiate into testes under the influence of SRY,the gene on the
sex-determining region of the Y chromosome.We will discuss what
is known regarding MIS signal transduction,which as with other members
of the TGFß family ofgrowth and differentiation factors, occurs
through a heteromericcomplex of single transmembrane serine/threonine
kinase receptorsto effect downstream signaling events, including
Smad, nuclearfactor-B, ß-catenin, and p16 activation.
Finally,we will assess the clinical relevance of studying MIS in
patientswith persistent Müllerian duct syndrome and our efforts
todetermine the therapeutic value of MIS for patients with ovarianand
other MIS receptor-expressing cancers.
This article has been cited by other articles:
P. S. Tanwar, T. Kaneko-Tarui, L. Zhang, P. Rani, M. M. Taketo, and J. Teixeira Constitutive WNT/Beta-Catenin Signaling in Murine Sertoli Cells Disrupts Their Differentiation and Ability to Support Spermatogenesis
Biol Reprod,
February 1, 2010;
82(2):
422 - 432.
[Abstract][Full Text][PDF]
T. Eldar-Geva, G. Liberty, B. Chertin, A. Fridmans, A. Farkas, E. J Margalioth, and I. M Spitz Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer
Eur. J. Endocrinol.,
January 1, 2010;
162(1):
177 - 181.
[Abstract][Full Text][PDF]
B. S. Middlebrook, K. Eldin, X. Li, S. Shivasankaran, and S. A. Pangas Smad1-Smad5 Ovarian Conditional Knockout Mice Develop a Disease Profile Similar to the Juvenile Form of Human Granulosa Cell Tumors
Endocrinology,
December 1, 2009;
150(12):
5208 - 5217.
[Abstract][Full Text][PDF]
J. F. Dorgan, F. Z. Stanczyk, B. L. Egleston, L. L. Kahle, C. M. Shaw, C. S. Spittle, A. K. Godwin, and L. A. Brinton Prospective Case-Control Study of Serum Mullerian Inhibiting Substance and Breast Cancer Risk
J Natl Cancer Inst,
November 4, 2009;
101(21):
1501 - 1509.
[Abstract][Full Text][PDF]
P.-Y. Wang, A. Protheroe, A. N. Clarkson, F. Imhoff, K. Koishi, and I. S. McLennan Mullerian inhibiting substance contributes to sex-linked biases in the brain and behavior
PNAS,
April 28, 2009;
106(17):
7203 - 7208.
[Abstract][Full Text][PDF]
P. J. Malloy, L. Peng, J. Wang, and D. Feldman Interaction of the Vitamin D Receptor with a Vitamin D Response Element in the Mullerian-Inhibiting Substance (MIS) Promoter: Regulation of MIS Expression by Calcitriol in Prostate Cancer Cells
Endocrinology,
April 1, 2009;
150(4):
1580 - 1587.
[Abstract][Full Text][PDF]
C. Rico, S. Fabre, C. Medigue, N. d. Clemente, F. Clement, M. Bontoux, J.-L. Touze, M. Dupont, E. Briant, B. Remy, et al. Anti-Mullerian Hormone Is an Endocrine Marker of Ovarian Gonadotropin-Responsive Follicles and Can Help to Predict Superovulatory Responses in the Cow
Biol Reprod,
January 1, 2009;
80(1):
50 - 59.
[Abstract][Full Text][PDF]
D. Monniaux, N. d. Clemente, J.-L. Touze, C. Belville, C. Rico, M. Bontoux, J.-Y. Picard, and S. Fabre Intrafollicular Steroids and Anti-Mullerian Hormone During Normal and Cystic Ovarian Follicular Development in the Cow
Biol Reprod,
August 1, 2008;
79(2):
387 - 396.
[Abstract][Full Text][PDF]
A.A. Sinisi, D. Esposito, L. Maione, M.C. Quinto, D. Visconti, A. De Bellis, A. Bellastella, G. Conzo, and G. Bellastella Seminal anti-Mullerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism
Hum. Reprod.,
May 1, 2008;
23(5):
1029 - 1034.
[Abstract][Full Text][PDF]
R. S. Viger, S. M. Guittot, M. Anttonen, D. B. Wilson, and M. Heikinheimo Role of the GATA Family of Transcription Factors in Endocrine Development, Function, and Disease
Mol. Endocrinol.,
April 1, 2008;
22(4):
781 - 798.
[Abstract][Full Text][PDF]
N. Renlund, R. Pieretti-Vanmarcke, F. H. O'Neill, L. Zhang, P. K. Donahoe, and J. Teixeira c-Jun N-terminal Kinase Inhibitor II (SP600125) Activates Mullerian Inhibiting Substance Type II Receptor-Mediated Signal Transduction
Endocrinology,
January 1, 2008;
149(1):
108 - 115.
[Abstract][Full Text][PDF]
B. Kohler, A.-L. Delezoide, B. Boizet-Bonhoure, M. J McPhaul, C. Sultan, and S. Lumbroso Coexpression of Wilms' tumor suppressor 1 (WT1) and androgen receptor (AR) in the genital tract of human male embryos and regulation of AR promoter activity by WT1
J. Mol. Endocrinol.,
May 1, 2007;
38(5):
547 - 554.
[Abstract][Full Text][PDF]
X. Yin, S. Ouyang, W. Xu, X. Zhang, K. L. Fok, H. Y. Wong, J. Zhang, X. Qiu, S. Miao, H. C. Chan, et al. YWK-II protein as a novel Go-coupled receptor for Mullerian inhibiting substance in cell survival
J. Cell Sci.,
May 1, 2007;
120(9):
1521 - 1528.
[Abstract][Full Text][PDF]
T. T. Tran, D. L. Segev, V. Gupta, H. Kawakubo, G. Yeo, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Regulates Androgen-Induced Gene Expression and Growth in Prostate Cancer Cells through a Nuclear Factor-{kappa}B-Dependent Smad-Independent Mechanism
Mol. Endocrinol.,
October 1, 2006;
20(10):
2382 - 2391.
[Abstract][Full Text][PDF]
T. Ebner, M. Sommergruber, M. Moser, O. Shebl, E. Schreier-Lechner, and G. Tews Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles
Hum. Reprod.,
August 1, 2006;
21(8):
2022 - 2026.
[Abstract][Full Text][PDF]
Y. Zhan, A. Fujino, D. T. MacLaughlin, T. F. Manganaro, P. P. Szotek, N. A. Arango, J. Teixeira, and P. K. Donahoe Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression
Development,
June 15, 2006;
133(12):
2359 - 2369.
[Abstract][Full Text][PDF]
R. Pieretti-Vanmarcke, P. K. Donahoe, P. Szotek, T. Manganaro, M. K. Lorenzen, J. Lorenzen, D. C. Connolly, E. F. Halpern, and D. T. MacLaughlin Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo
Clin. Cancer Res.,
March 1, 2006;
12(5):
1593 - 1598.
[Abstract][Full Text][PDF]
M. Anttonen, L. Unkila-Kallio, A. Leminen, R. Butzow, and M. Heikinheimo High GATA-4 Expression Associates with Aggressive Behavior, whereas Low Anti-Mullerian Hormone Expression Associates with Growth Potential of Ovarian Granulosa Cell Tumors
J. Clin. Endocrinol. Metab.,
December 1, 2005;
90(12):
6529 - 6535.
[Abstract][Full Text][PDF]
P.-Y. Wang, K. Koishi, A. B. McGeachie, M. Kimber, D. T. MacLaughlin, P. K. Donahoe, and I. S. McLennan Mullerian Inhibiting Substance acts as a motor neuron survival factor in vitro
PNAS,
November 8, 2005;
102(45):
16421 - 16425.
[Abstract][Full Text][PDF]
R. A. Rey, E. Codner, G. Iniguez, P. Bedecarras, R. Trigo, C. Okuma, S. Gottlieb, I. Bergada, S. M. Campo, and F. G. Cassorla Low Risk of Impaired Testicular Sertoli and Leydig Cell Functions in Boys with Isolated Hypospadias
J. Clin. Endocrinol. Metab.,
November 1, 2005;
90(11):
6035 - 6040.
[Abstract][Full Text][PDF]
A. La Marca, S. Giulini, R. Orvieto, V. De Leo, and A. Volpe Anti-Mullerian hormone concentrations in maternal serum during pregnancy
Hum. Reprod.,
June 1, 2005;
20(6):
1569 - 1572.
[Abstract][Full Text][PDF]
V. Gupta, J. L. Carey, H. Kawakubo, A. Muzikansky, J. E. Green, P. K. Donahoe, D. T. MacLaughlin, and S. Maheswaran Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model
PNAS,
March 1, 2005;
102(9):
3219 - 3224.
[Abstract][Full Text][PDF]
R. S. Viger, H. Taniguchi, N. M. Robert, and J. J. Tremblay The 25th Volume: Role of the GATA Family of Transcription Factors in Andrology
J Androl,
July 1, 2004;
25(4):
441 - 452.
[Full Text][PDF]
C. J. Jorgez, M. Klysik, S. P. Jamin, R. R. Behringer, and M. M. Matzuk Granulosa Cell-Specific Inactivation of Follistatin Causes Female Fertility Defects
Mol. Endocrinol.,
April 1, 2004;
18(4):
953 - 967.
[Abstract][Full Text][PDF]
C. P. Houk, E. J. Pearson, N. Martinelle, P. K. Donahoe, and J. Teixeira Feedback Inhibition of Steroidogenic Acute Regulatory Protein Expression in Vitro and in Vivo by Androgens
Endocrinology,
March 1, 2004;
145(3):
1269 - 1275.
[Abstract][Full Text][PDF]
A. Salva, M. P. Hardy, X.-f. Wu, C. M. Sottas, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee Mullerian-Inhibiting Substance Inhibits Rat Leydig Cell Regeneration after Ethylene Dimethanesulphonate Ablation
Biol Reprod,
March 1, 2004;
70(3):
600 - 607.
[Abstract][Full Text][PDF]
D. T. MacLaughlin and P. K. Donahoe Sex Determination and Differentiation
N. Engl. J. Med.,
January 22, 2004;
350(4):
367 - 378.
[Full Text][PDF]
Y. Hoshiya, V. Gupta, H. Kawakubo, E. Brachtel, J. L. Carey, L. Sasur, A. Scott, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Promotes Interferon {gamma}-induced Gene Expression and Apoptosis in Breast Cancer Cells
J. Biol. Chem.,
December 19, 2003;
278(51):
51703 - 51712.
[Abstract][Full Text][PDF]
J. J. Tremblay and R. S. Viger A Mutated Form of Steroidogenic Factor 1 (SF-1 G35E) That Causes Sex Reversal in Humans Fails to Synergize with Transcription Factor GATA-4
J. Biol. Chem.,
October 24, 2003;
278(43):
42637 - 42642.
[Abstract][Full Text][PDF]
C. Y. Hong, J. H. Park, K. H. Seo, J.-M. Kim, S. Y. Im, J. W. Lee, H.-S. Choi, and K. Lee Expression of MIS in the Testis Is Downregulated by Tumor Necrosis Factor Alpha through the Negative Regulation of SF-1 Transactivation by NF-{kappa}B
Mol. Cell. Biol.,
September 1, 2003;
23(17):
6000 - 6012.
[Abstract][Full Text][PDF]
G. Y. Bedecarrats, F. H. O'Neill, E. R. Norwitz, U. B. Kaiser, and J. Teixeira Regulation of gonadotropin gene expression by Mullerian inhibiting substance
PNAS,
August 5, 2003;
100(16):
9348 - 9353.
[Abstract][Full Text][PDF]
C. Lukas-Croisier, C. Lasala, J. Nicaud, P. Bedecarras, T. R. Kumar, M. Dutertre, M. M. Matzuk, J.-Y. Picard, N. Josso, and R. Rey Follicle-Stimulating Hormone Increases Testicular Anti-Mullerian Hormone (AMH) Production through Sertoli Cell Proliferation and a Nonclassical Cyclic Adenosine 5'-Monophosphate-Mediated Activation of the AMH Gene
Mol. Endocrinol.,
April 1, 2003;
17(4):
550 - 561.
[Abstract][Full Text][PDF]
D. C. Connolly, R. Bao, A. Y. Nikitin, K. C. Stephens, T. W. Poole, X. Hua, S. S. Harris, B. C. Vanderhyden, and T. C. Hamilton Female Mice Chimeric for Expression of the Simian Virus 40 TAg under Control of the MISIIR Promoter Develop Epithelial Ovarian Cancer
Cancer Res.,
March 15, 2003;
63(6):
1389 - 1397.
[Abstract][Full Text][PDF]
M. Misra, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee The Role of Mullerian Inhibiting Substance in the Evaluation of Phenotypic Female Patients with Mild Degrees of Virilization
J. Clin. Endocrinol. Metab.,
February 1, 2003;
88(2):
787 - 792.
[Abstract][Full Text][PDF]
R. Fanchin, L. M. Schonauer, C. Righini, N. Frydman, R. Frydman, and J. Taieb Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation
Hum. Reprod.,
February 1, 2003;
18(2):
328 - 332.
[Abstract][Full Text][PDF]
H. Chang, C. W. Brown, and M. M. Matzuk Genetic Analysis of the Mammalian Transforming Growth Factor-{beta} Superfamily
Endocr. Rev.,
December 1, 2002;
23(6):
787 - 823.
[Abstract][Full Text][PDF]
Y. Kubota, C. Temelcos, R.A.D. Bathgate, K.J. Smith, D. Scott, C. Zhao, and J.M. Hutson The role of insulin 3, testosterone, Mullerian inhibiting substance and relaxin in rat gubernacular growth
Mol. Hum. Reprod.,
October 1, 2002;
8(10):
900 - 905.
[Abstract][Full Text][PDF]
V. M. Laurich, A. M. Trbovich, F. H. O'Neill, C. P. Houk, P. M. Sluss, A. H. Payne, P. K. Donahoe, and J. Teixeira Mullerian Inhibiting Substance Blocks the Protein Kinase A-Induced Expression of Cytochrome P450 17{alpha}-Hydroxylase/C17-20 Lyase mRNA in a Mouse Leydig Cell Line Independent of cAMP Responsive Element Binding Protein Phosphorylation
Endocrinology,
September 1, 2002;
143(9):
3351 - 3360.
[Abstract][Full Text][PDF]
M. Misra, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee Measurement of Mullerian Inhibiting Substance Facilitates Management of Boys with Microphallus and Cryptorchidism
J. Clin. Endocrinol. Metab.,
August 1, 2002;
87(8):
3598 - 3602.
[Abstract][Full Text][PDF]
A. E. Stephen, L. A. Pearsall, B. P. Christian, P. K. Donahoe, J. P. Vacanti, and D. T. MacLaughlin Highly Purified Mullerian Inhibiting Substance Inhibits Human Ovarian Cancer in Vivo
Clin. Cancer Res.,
August 1, 2002;
8(8):
2640 - 2646.
[Abstract][Full Text][PDF]